ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2025
Dextranomer/hyaluronic acid injections for patients with vesicoureteral reflux Does the age at injection predict the outcome?
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to assess the impact of age of the initial dextranomer/hyaluronic acid (Dx/HA) injection on the subsequent outcome, including the need for repeated injections.
methodsThe charts of patients who underwent Dx/HA injection from 2010-2020 were retrospectively reviewed. Two groups were created according to the number of Dx/HA injections: single vs. repeated injections. Patients who presented with antenatal hydronephrosis, neurogenic bladder, and followup less than one year after the first injection were excluded. Repeated Dx/HA injections were indicated in patients with documented vesicoureteric reflux (VUR) who experienced recurrent febrile urinary tract infection (fUTI) postoperatively.
resultsA total of 172 patients with 189 renal units were included; 139 (73.5%) units underwent single injections, whereas 50 (26.5%) had repeated injections. Twenty-three (48.9%) patients with repeated injections presented before the age of one year vs. 24 (51.1%) after the age of one year (p=0.02). Of the repeated group, 34 (68%) units received two injections, 14 (28%) were injected three times or more, and two (4%) had other treatment modalities. Forty-four percent of units requiring repeated injections had high-grade VUR (grades 4 and 5), compared to only 22.3% of those successfully treated with a single injection (p=0.003).
conclusionsIn our cohort, 26.5% of renal units underwent repeated Dx/HA injections. Forty-four percent of units with repeated injections had grade 4-5 VUR. Patients with VUR who were injected or presented with fUTI before the age of one year old were at higher risk of repeated injections than those who were injected or presented later.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.